Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Parkinson’s disease affects more than 10 million people worldwide. Discover its causes, symptoms, and the latest innovations ...

Ventyx Biosciences (NASDAQ:VTYX) announced Tuesday that a small mid-stage trial for VTX3232, its experimental therapy for Parkinson’s disease, reached the primary endpoint related to safety and ...

Discover how Parkinson's disease begins in the gut, not the brain. Learn the early digestive warning signs that appear years ...

Bill Plaschke, the award-winning sports columnist and longtime "Around the Horn" panelist, announced his Parkinson's ...

Los Angeles Times readers give their thoughts on Bill Plaschke's poignant column on Parkinson's disease, the Dodgers and the ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...

A team of researchers at UCLA has developed a high-tech diagnostic pen that can detect signs of Parkinson’s disease with over ...

A new study suggests long-term exposure to chemicals used to keep fairways green may be tied to an increased risk of ...

MJFF co-founder and CEO Deborah W. Brooks read a letter of gratitude from Michael J. Fox for the support of the mission from ...

May 27, 2025 — Persons with Parkinson's disease increasingly lose their mobility over time and are eventually unable to walk. Hope for these patients rests on deep brain stimulation, also known ...

Roche to advance prasinezumab into phase III development for early-stage Parkinson's disease: Basel Tuesday, June 17, 2025, 09:00 Hrs [IST] Roche announced its decision to proceed ...